The Common Immunogenic Etiology of Chronic Fatigue Syndrome: From Infections to Vaccines via Adjuvants to the ASIA Syndrome

Infectious Disease Clinics of North America

Volumn 25, Issue 4, 2011, Pages 851-863

  Rosenblum, Hemda ^a   Shoenfeld, Yehuda ^a   Amital, Howard ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adjuvants; ASIA syndrome; Autoimmunity; Chronic fatigue syndrome; Vaccinations

Indexed keywords

CORTICOTROPIN; IMMUNOLOGICAL ADJUVANT; NEUROPEPTIDE Y; SILICONE;

AUTOINFLAMMATORY DISEASE; BACTERIAL INFECTION; CAUSAL ATTRIBUTION; CHRONIC FATIGUE SYNDROME; COGNITIVE THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; EXERCISE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOPATHOLOGY; LIFESTYLE MODIFICATION; NONHUMAN; PERSONALITY; PROGNOSIS; PROTEIN FUNCTION; RETROVIRUS INFECTION; REVIEW; THERAPY EFFECT; VACCINATION REACTION; XENOTROPIC MULV RELATED VIRUS;

ADJUVANTS, IMMUNOLOGIC; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; FATIGUE SYNDROME, CHRONIC; HUMANS; LIFE STYLE; VACCINES; VIRUS DISEASES;

EID: 80455176668     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.07.012     Document Type: Review

References (101)

1. Prins J.B., van der Meer J.W., Bleijenberg G. Chronic fatigue syndrome. Lancet 2006, 367:346-355.
2. Michiels V., Cluydts R. Neuropsychological functioning in chronic fatigue syndrome: a review. Acta Psychiatr Scand 2001, 103:84-93.
3. Bassi N., Amital D., Amital H., et al. Chronic fatigue syndrome: characteristics and possible causes for its pathogenesis. Isr Med Assoc J 2008, 10:79-82.
4. Reyes M., Nisenbaum R., Hoaglin D.C., et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med 2003, 163:1530-1536.
5. Working Group of the Royal Australasian College of Physicians Chronic fatigue syndrome. Clinical practice guidelines-2002. Med J Aust 2002, 176(Suppl):S23-S56.
6. Fukuda K., Straus S.E., Hickie I., et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994, 121:953-959.
7. Matthews D.A., Lane T.J., Manu P. Definition of the chronic fatigue syndrome. Ann Intern Med 1988, 109:511-512.
8. Griffith J.P., Zarrouf F.A. A systematic review of chronic fatigue syndrome: don't assume it's depression. Prim Care Companion J Clin Psychiatry 2008, 10:120-128.
9. Candy B., Chalder T., Cleare A.J., et al. A randomised controlled trial of a psycho-educational intervention to aid recovery in infectious mononucleosis. J Psychosom Res 2004, 57:89-94.
10. Katz B.Z., Shiraishi Y., Mears C.J., et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics 2009, 124:189-193.
11. Moss-Morris R., Spence M.J., Hou R. The pathway from glandular fever to chronic fatigue syndrome: can the cognitive behavioural model provide the map?. Psychol Med 2011, 41:1099-1107.
12. Vollmer-Conna U. Chronic fatigue syndrome in adolescence: where to from here?. Arch Pediatr Adolesc Med 2010, 164:880-881.
13. Harvey S.B., Wessely S., Kuh D., et al. The relationship between fatigue and psychiatric disorders: evidence for the concept of neurasthenia. J Psychosom Res 2009, 66:445-454.
14. Hatcher S., House A. Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case-control study. Psychol Med 2003, 33:1185-1192.
15. Viner R., Hotopf M. Childhood predictors of self reported chronic fatigue syndrome/myalgic encephalomyelitis in adults: national birth cohort study. BMJ 2004, 329:941.
16. Rangel L., Garralda M.E., Jeffs J., et al. Family health and characteristics in chronic fatigue syndrome, juvenile rheumatoid arthritis, and emotional disorders of childhood. J Am Acad Child Adolesc Psychiatry 2005, 44:150-158.
17. Endicott N.A. Chronic fatigue syndrome in private practice psychiatry: family history of physical and mental health. J Psychosom Res 1999, 47:343-354.
18. Heim C., Wagner D., Maloney E., et al. Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study. Arch Gen Psychiatry 2006, 63:1258-1266.
19. Morriss R., Sharpe M., Sharpley A.L., et al. Abnormalities of sleep in patients with the chronic fatigue syndrome. BMJ 1993, 306:1161-1164.
20. Morriss R.K., Wearden A.J., Battersby L. The relation of sleep difficulties to fatigue, mood and disability in chronic fatigue syndrome. J Psychosom Res 1997, 42:597-605.
21. Friedlander A.H., Mahler M.E., Yagiela J.A. Restless legs syndrome: manifestations, treatment and dental implications. J Am Dent Assoc 2006, 137:755-761.
22. Salit I.E. Precipitating factors for the chronic fatigue syndrome. J Psychiatr Res 1997, 31:59-65.
23. Evengard B., Jonzon E., Sandberg A., et al. Differences between patients with chronic fatigue syndrome and with chronic fatigue at an infectious disease clinic in Stockholm, Sweden. Psychiatry Clin Neurosci 2003, 57:361-368.
24. Klimas N.G., Salvato F.R., Morgan R., et al. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990, 28:1403-1410.
25. Masuda A., Nakayama T., Yamanaka T., et al. The prognosis after multidisciplinary treatment for patients with postinfectious chronic fatigue syndrome and noninfectious chronic fatigue syndrome. J Behav Med 2002, 25:487-497.
26. Lane R.J., Soteriou B.A., Zhang H., et al. Enterovirus related metabolic myopathy: a postviral fatigue syndrome. J Neurol Neurosurg Psychiatry 2003, 74:1382-1386.
27. Fletcher M.A., Rosenthal M., Antoni M., et al. Plasma neuropeptide Y: a biomarker for symptom severity in chronic fatigue syndrome. Behav Brain Funct 2010, 6:76.
28. Chia J.K., Chia A.Y. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol 2008, 61:43-48.
29. Appel S., Chapman J., Shoenfeld Y. Infection and vaccination in chronic fatigue syndrome: myth or reality?. Autoimmunity 2007, 40:48-53.
30. Chia J.K. The role of enterovirus in chronic fatigue syndrome. J Clin Pathol 2005, 58:1126-1132.
31. Yousef G.E., Bell E.J., Mann G.F., et al. Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet 1988, 1:146-150.
32. Cunningham L., Bowles N.E., Lane R.J., et al. Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J Gen Virol 1990, 71(Pt 6):1399-1402.
33. Galbraith D.N., Nairn C., Clements G.B. Phylogenetic analysis of short enteroviral sequences from patients with chronic fatigue syndrome. J Gen Virol 1995, 76(Pt 7):1701-1707.
34. Douche-Aourik F., Berlier W., Feasson L., et al. Detection of enterovirus in human skeletal muscle from patients with chronic inflammatory muscle disease or fibromyalgia and healthy subjects. J Med Virol 2003, 71:540-547.
35. Kerr J.R. Enterovirus infection of the stomach in chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol 2008, 61:1-2.
36. Lombardi V.C., Ruscetti F.W., Das G.J., et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009, 326:585-589.
37. Fostel J., Boneva R., Lloyd A. Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis. Pharmacogenomics 2006, 7:441-454.
38. Buchwald D., Herrell R., Ashton S., et al. A twin study of chronic fatigue. Psychosom Med 2001, 63:936-943.
39. Hickie I., Kirk K., Martin N. Unique genetic and environmental determinants of prolonged fatigue: a twin study. Psychol Med 1999, 29:259-268.
40. Cho H.J., Skowera A., Cleare A., et al. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. Curr Opin Psychiatry 2006, 19:67-73.
41. Smith J., Fritz E.L., Kerr J.R., et al. Association of chronic fatigue syndrome with human leucocyte antigen class II alleles. J Clin Pathol 2005, 58:860-863.
42. Ortega-Hernandez O.D., Cuccia M., Bozzini S., et al. Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms?. Ann N Y Acad Sci 2009, 1173:589-599.
43. Bates D.W., Buchwald D., Lee J., et al. Clinical laboratory test findings in patients with chronic fatigue syndrome. Arch Intern Med 1995, 155:97-103.
44. Sabath D.E., Barcy S., Koelle D.M., et al. Cellular immunity in monozygotic twins discordant for chronic fatigue syndrome. J Infect Dis 2002, 185:828-832.
45. Lorusso L., Mikhaylova S.V., Capelli E., et al. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8:287-291.
46. Rasmussen A.K., Nielsen H., Andersen V., et al. Chronic fatigue syndrome-a controlled cross sectional study. J Rheumatol 1994, 21:1527-1531.
47. Landay A.L., Jessop C., Lennette E.T., et al. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991, 338:707-712.
48. Robertson M.J., Schacterle R.S., Mackin G.A., et al. Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin Exp Immunol 2005, 141:326-332.
49. Lloyd A., Hickie I., Brockman A., et al. Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects. J Infect Dis 1991, 164:1023-1024.
50. Staines D.R. Postulated vasoactive neuropeptide autoimmunity in fatigue-related conditions: a brief review and hypothesis. Clin Dev Immunol 2006, 13:25-39.
51. Nishikai M. Nippon Rinsho 2007, 65:1067-1070. [in Japanese].
52. Vernon S.D., Reeves W.C. Evaluation of autoantibodies to common and neuronal cell antigens in Chronic Fatigue Syndrome. J Autoimmune Dis 2005, 2:5.
53. Wheatland R. Chronic ACTH autoantibodies are a significant pathological factor in the disruption of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome, anorexia nervosa and major depression. Med Hypotheses 2005, 65:287-295.
54. Gottschalk M., Kumpfel T., Flachenecker P., et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 2005, 62:277-280.
55. Wessely S. The neuropsychiatry of chronic fatigue syndrome. Ciba Found Symp 1993, 173:212-229.
56. Cleare A.J. The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol Metab 2004, 15:55-59.
57. Gaab J., Engert V., Heitz V., et al. Associations between neuroendocrine responses to the Insulin Tolerance Test and patient characteristics in chronic fatigue syndrome. J Psychosom Res 2004, 56:419-424.
58. Bakheit A.M., Behan P.O., Dinan T.G., et al. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ 1992, 304:1010-1012.
59. Kuo L.E., Abe K., Zukowska Z. Stress, NPY and vascular remodeling: implications for stress-related diseases. Peptides 2007, 28:435-440.
60. Kuo L.E., Kitlinska J.B., Tilan J.U., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007, 13:803-811.
61. Peterson P.K., Schenck C.H., Sherman R. Chronic fatigue syndrome in Minnesota. Minn Med 1991, 74:21-26.
62. Holmes G.P., Kaplan J.E., Gantz N.M., et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988, 108:387-389.
63. Peterson P.K., Sirr S.A., Grammith F.C., et al. Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients. Clin Diagn Lab Immunol 1994, 1:222-226.
64. Fulle S., Belia S., Vecchiet J., et al. Modification of the functional capacity of sarcoplasmic reticulum membranes in patients suffering from chronic fatigue syndrome. Neuromuscul Disord 2003, 13:479-484.
65. Murphy M.E., Kehrer J.P. Oxidative stress and muscular dystrophy. Chem Biol Interact 1989, 69:101-173.
66. Jammes Y., Steinberg J.G., Mambrini O., et al. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 2005, 257:299-310.
67. MacDonald K.L., Osterholm M.T., LeDell K.H., et al. A case-control study to assess possible triggers and cofactors in chronic fatigue syndrome. Am J Med 1996, 100:548-554.
68. Price J.R., Couper J. Cognitive behaviour therapy for adults with chronic fatigue syndrome. Cochrane Database Syst Rev 2000, 2. CD001027.
69. Akagi H., Klimes I., Bass C. Cognitive behavioral therapy for chronic fatigue syndrome in a general hospital-feasible and effective. Gen Hosp Psychiatry 2001, 23:254-260.
70. Deale A., Husain K., Chalder T., et al. Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study. Am J Psychiatry 2001, 158:2038-2042.
71. Deale A., Chalder T., Marks I., et al. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry 1997, 154:408-414.
72. O'Dowd H., Gladwell P., Rogers C.A., et al. Cognitive behavioural therapy in chronic fatigue syndrome: a randomised controlled trial of an outpatient group programme. Health Technol Assess 2006, 10:iii-iix. 1.
73. Cleare A.J., Heap E., Malhi G.S., et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999, 353:455-458.
74. McKenzie R., O'Fallon A., Dale J., et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. JAMA 1998, 280:1061-1066.
75. Vercoulen J.H., Swanink C.M., Zitman F.G., et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996, 347:858-861.
76. Natelson B.H., Cheu J., Hill N., et al. Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology 1998, 37:150-154.
77. Wearden A.J., Morriss R.K., Mullis R., et al. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 1998, 172:485-490.
78. White P.D., Cleary K.J. An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. Int Clin Psychopharmacol 1997, 12:47-52.
79. Vollmer-Conna U., Hickie I., Hadzi-Pavlovic D., et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997, 103:38-43.
80. Williams G., Waterhouse J., Mugarza J., et al. Therapy of circadian rhythm disorders in chronic fatigue syndrome: no symptomatic improvement with melatonin or phototherapy. Eur J Clin Invest 2002, 32:831-837.
81. McDermott C., Richards S.C., Thomas P.W., et al. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. QJM 2006, 99:461-468.
82. Shoenfeld Y., gmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
83. gmon-Levin N., Zafrir Y., Paz Z., et al. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 2009, 18:1192-1197.
84. Altman A., Szyper-Kravitz M., Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association?. Rheumatol Int 2008, 28:609-612.
85. Nancy A.L., Shoenfeld Y. Chronic fatigue syndrome with autoantibodies-the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008, 8:52-55.
86. Sanchez-Guerrero J., Colditz G.A., Karlson E.W., et al. Silicone breast implants and the risk of connective-tissue diseases and symptoms. N Engl J Med 1995, 332:1666-1670.
87. Bryant H., Brasher P. Breast implants and breast cancer-reanalysis of a linkage study. N Engl J Med 1995, 332:1535-1539.
88. Angell M. Do breast implants cause systemic disease? Science in the courtroom. N Engl J Med 1994, 330:1748-1749.
89. Kessler D.A. The basis of the FDA's decision on breast implants. N Engl J Med 1992, 326:1713-1715.
90. House A. Alleged link between hepatitis B vaccine and chronic fatigue syndrome. CMAJ 1992, 146:1145.
91. Halperin S.A., Dobson S., McNeil S., et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006, 24:20-26.
92. Shoaib B.O., Patten B.M. Human adjuvant disease: presentation as a multiple sclerosis-like syndrome. South Med J 1996, 89:179-188.
93. Vasey F.B., Zarabadi S.A., Seleznick M., et al. Where there's smoke there's fire: the silicone breast implant controversy continues to flicker: a new disease that needs to be defined. J Rheumatol 2003, 30:2092-2094.
94. Kivity S., Fireman E., Greif J., et al. Effect of budesonide on bronchial hyperresponsiveness and pulmonary function in patients with mild to moderate asthma. Ann Allergy 1994, 72:333-336.
95. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
96. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 1998, 352:347-352.
97. Exley C., Swarbrick L., Gherardi R.K., et al. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 2009, 72:135-139.
98. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124:1821-1831.
99. Hotopf M., David A., Hull L., et al. Role of vaccinations as risk factors for ill health in veterans of the Gulf war: cross sectional study. BMJ 2000, 320:1363-1367.
100. Kumar V., Bal A., Gill K.D. Impairment of mitochondrial energy metabolism in different regions of rat brain following chronic exposure to aluminium. Brain Res 2008, 1232:94-103.
101. Kumar V., Gill K.D. Aluminium neurotoxicity: neurobehavioural and oxidative aspects. Arch Toxicol 2009, 83:965-978.